HeartBeam to Host Fourth Quarter Full Year 2025 Results Conference Call on Thursday, March 12, 2026 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a pioneering medical technology firm specializing in advanced cardiac care solutions, is scheduled to host a conference call on Thursday, March 12, 2026, at 4:30 p.m. Eastern Time. The call will address the company's financial performance for the fourth quarter and full year ending December 31, 2025, alongside strategic updates regarding its innovative 12-lead ECG extended wear patch and its limited commercial launch.

CEO Robert Eno, CFO Timothy Cruickshank, and newly appointed Chief Commercial Officer Bryan Humbarger will lead the discussion, followed by a question-and-answer session. A press release with detailed financial results will be released prior to the call, enabling investors and analysts to review the company's performance and projections.

HeartBeam is on the cutting edge of cardiac technology, creating the first-ever cable-free device capable of gathering ECG signals from three non-coplanar directions to produce a comprehensive 12-lead ECG. This groundbreaking platform is designed for ease of use, allowing for actionable heart intelligence to be harnessed outside conventional medical settings. HeartBeam's technology aims to empower physicians with the ability to identify both acute cardiac events and long-term health trends, thereby enhancing patient care and potentially saving lives.

Following the call, a presentation and video will be made available on the company's investor relations website. Those wishing to participate in the call can do so by dialling 1-844-826-3035 (U.S.) or 1-412-317-5195 (international), with the conference code 10206235. A replay of the call will be accessible shortly after its conclusion, lasting until March 26, 2026. For further details, interested parties can refer to HeartBeam's official website.

HeartBeam, Inc. (NASDAQ: BEAT) is set to hold its fourth quarter and full-year results conference call on March 12, 2026, at 4:30 p.m. Eastern Time. As an analyst, there are key takeaways for investors to consider ahead of this call.

First and foremost, monitor the announcements regarding HeartBeam’s limited commercial launch and particularly its 12-lead ECG extended wear patch technology. With a unique value proposition of providing portable cardiac intelligence through 3D ECG technology, HeartBeam stands at the forefront of transforming cardiac care. The FDA's recent clearance of its software for arrhythmia assessment adds to the credibility and potential market acceptance of its product portfolio.

Analysts should pay close attention to the company's financial performance metrics during the call. Strong revenue growth, especially against the backdrop of the ongoing commercial launch, will bolster investor confidence. Any projection updates or changed guidance by HeartBeam's management will also be crucial indicators of how the company anticipates navigating the market landscape in 2026.

The leadership team, including CEO Robert Eno and CFO Timothy Cruickshank, will provide insights into strategic initiatives that could foster growth. Additionally, the inclusion of Chief Commercial Officer Bryan Humbarger signifies a strong commitment to commercial execution; thus, investors should evaluate any commentary around sales strategies and partnerships.

Moreover, the market's appetite for innovative health tech solutions remains high, primarily influenced by ongoing trends toward remote patient monitoring. If HeartBeam can effectively communicate its advancements and strategic plans, it may draw heightened interest from institutional investors.

In conclusion, keeping an eye on HeartBeam’s technological developments and financial outlook during the call will provide critical insights for potential investment decisions in this transformative healthcare company.